Formulation and Evaluation of Solid Lipid Nanoparticle Based Transdermal Drug Delivery System for Alzheimer's Disease

Salve, Pramod S.; Pise, Suvarna; Bali, Nikhil

doi:10.5958/0975-4377.2016.00011.2

Cited by 11 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid nanoparticle dispersion was produced by gradually cooling the warm emulsion below the lipid crystallization temperature. Ultra centrifugation could be used to generate a concentrated lipid nanoparticles dispersion formulation of drug-loaded SLNs prepared by ultrasonication method [F-4] [15].…”

Section: High Shear Homogenization And/or Ultrasonication Techniquementioning

confidence: 99%

Optimization, Characterization and in Vivo Study of Rivastigmine Tartrate Nanoparticles by Using 22 Full Factorial Design for Oral Delivery

2023

View full text Add to dashboard Cite

Objective: This research aims to optimize the solid lipid nanoparticles by using full factorial design to improve the delivery of rivastigmine tartrate (RT), which is used for the treatment of Alzheimer’s disease (AD). Solid lipid nanoparticles (SLNs) are attracting importance for drug developers due to their performance. The outcome of this research will lead to improvements in drug release and solubility of RT for better therapeutic effect. Methods: Four different methods were used to prepare solid lipid nanoparticles of rivastigmine tartrate, namely the modified solvent emulsification technique, the microemulsion cooling technique, the solvent injection technique, and the homogenization/ultrasonication technique. Glyceryl monostearate (GMS) was used as a lipid; Compritol 888, tween 80, and span 40 were used as surfactants, co-surfactants, and stabilizers, respectively. Results: SLNs were evaluated for zeta potential, particle size, polydispersity index, surface morphology, Fourier Transform Infrared Spectroscopy (FTIR), and differential scanning calorimetry (DSC). Entrapment efficiency and drug loading were also estimated. Solubility study of rivastigmine tartrate in different solid lipids as well as the in vitro drug release, was studied. The particle size of SLNs was found to range between 138.22+0.01 nm and 172.79+0.23 nm. The zeta potential of the optimized formulation was found to be in the the-24+0.01mV range, indicating a stable formulation. A scanning electron microscope indicates a clear spherical structure without any aggregation. Entrapment efficiency was determined to be 69.27+0.22%. The RT-SLNs showed significant retention in memory when compared with RT solution (standard formulation), which may be attributed to the lipid nature and nanostructure of the delivery system that may probably result in more accumulation of the drug in the brain to show better effect. Conclusion: The current study concludes that the microemulsion cooling technique is the best method for patient compliance and stability with all desired characteristics parameters.

show abstract

Section: High Shear Homogenization And/or Ultrasonication Techniquementioning

confidence: 99%

Optimization, Characterization and in Vivo Study of Rivastigmine Tartrate Nanoparticles by Using 22 Full Factorial Design for Oral Delivery

2023

View full text Add to dashboard Cite

show abstract

“…The formulation has been optimized by a total of 32 Factory Design 10 experts. Full drug release was observed after 24 h in the ex vivo analysis [ 73 ].…”

Section: Lipid Nanoparticles Effects On Amyloid Beta Peptidementioning

confidence: 99%

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Abbas

2021

Polymers

View full text Add to dashboard Cite

The disorder of Alzheimer’s is marked by progressive pathophysiological neurodegeneration. The amino acid peptides in the amyloid plaques found in the brains of people with Alzheimer’s disease (AD) are known as amyloid-beta (Aβ). Current treatments are not curative, and the effects associated with AD are reduced. Improving treatment results involved the targeting of drugs at optimum therapeutic concentration. Nanotechnology is seen as an unconventional, modern technology that plays a key role in the treatment of Alzheimer’s disease. Using nanoparticles, molecular detection, effective drug targeting, and their combination offer high sensitivity. The aim of this review is to shed light on the function and successful role of nanoparticles to resolve Aβ aggregation and thus to help cure Alzheimer’s disease. The analysis divides these nanoparticles into three categories: polymer, lipid, and gold nanoparticles. A thorough comparison was then made between the nanoparticles, which are used according to their role, properties, and size in the procedure. The nanoparticles can prevent the accumulation of Aβ during the efficient delivery of the drug to the cells to treat Alzheimer’s disease. Furthermore, this comparison demonstrated the ability of these nanoparticles to deal efficiently with Alzheimer’s disease. The role of these nanoparticles varied from delivering the drug to brain cells to dealing with the disease-causing peptide.

show abstract

Nanocarriers in Transdermal Drug Delivery

Desai

Pandya

Patel

2021

Nanocarriers: Drug Delivery System

View full text Add to dashboard Cite

Formulation and Evaluation of Solid Lipid Nanoparticle Based Transdermal Drug Delivery System for Alzheimer's Disease

Cited by 11 publications

References 0 publications

Optimization, Characterization and in Vivo Study of Rivastigmine Tartrate Nanoparticles by Using 22 Full Factorial Design for Oral Delivery

Optimization, Characterization and in Vivo Study of Rivastigmine Tartrate Nanoparticles by Using 22 Full Factorial Design for Oral Delivery

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Nanocarriers in Transdermal Drug Delivery

Contact Info

Product

Resources

About